Agilent Technology has increased its commitment to the continued development and enhancement of the Rosetta platforms
Agilent will provide these and other informatics products both individually and as integrated solutions to address existing and emerging life science applications.
"Our agreement with Agilent will benefit scientists who want to correlate data from multiple domains on an enterprise-wide level," said Yelena Shevelenko, general manager of Rosetta Biosoftware. "Together, Agilent and Rosetta will continue to provide improvements in gene expression analysis such as the recently released Ratio Splitter and Re-Ratio features, which give scientists a unique flexibility to analyse two-colour microarray data.
Agilent's increased investment makes it possible for us to bring these powerful advancements to life scientists at an accelerated pace".
"Ultimately, researchers want to assimilate disparate data about cell DNA, RNA, proteins, metabolites and pathways in order to develop a more comprehensive understanding of disease function and that is the focus of our new business unit," said Fran DiNuzzo, vice president and general manager of Agilent's Integrated Biology Solutions unit.
"Integrated software is critical to the advancement of integrated biology.
We are increasing our investments in life science informatics to facilitate these larger advances, and the Rosetta Resolver and Luminator systems are an important part of our solutions."
